Azurity Loses Hypertension Drug Patent Trial Against Alkem

By Ryan Davis · February 13, 2023, 10:00 PM EST

A federal judge sitting in Delaware ruled Friday that several claims of two patents on Azurity Pharmaceuticals Inc.'s hypertension drug Epaned are invalid, handing a win to Alkem Laboratories Ltd., which...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.

Case Number

1:19-cv-02100

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

November 05, 2019